Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
NEW YORK, March 24, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Eastern District of Pennsylvania on behalf of investors who purchased Innocoll Holdings plc (NASDAQ:INNL) securities between March 17, 2016 and December 29, 2016.
Click here to learn about the case: http://www.wongesq.com/pslra/innocoll-holdings-plc. There is no cost or obligation to you.
According to the complaint, throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) Innocoll’s New Drug Application (“NDA”) submission to the FDA in October 2016 for XARACOLL was incomplete; (2) due to the incomplete NDA submission, XARACOLL would not be approved in 2017 as investors were led to believe; and (3) as a result, Defendants’ statements about Innocoll’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.
If you suffered a loss in Innocoll you have until March 27, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/innocoll-holdings-plc.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
